Mild and Efficient Cobalt-Catalyzed Cross-Coupling of Aliphatic Amides and Aryl Iodides in Water
作者:Yong-Chua Teo、Bryan Tan
DOI:10.1055/s-0034-1380724
日期:——
convenient protocol for the C–N cross-coupling of aliphatic amides and iodobenzene is demonstrated using a simple and inexpensive Co(C2O4)·2H2O/N,N′-dimethylethylenediamine (DMEDA) catalytic system in water. Good yields of N-arylated products were isolated (up to 85%) and the protocol has been successfully applied to the synthesis of the anticancer drug, flutamide.
Reductive Acylation of Nitroarenes to Anilides by Sodium Sulfite in Carboxylic Acids
作者:Mohammad Ghaffarzadeh、Pegah Akhavan
DOI:10.1246/cl.140454
日期:2014.9.5
A facile and efficient reductive acylation of aromatic nitro compounds to corresponding anilides using a sodium sulfite–carboxylic acid system for the first time has been reported. The sodium sulfi...
首次报道了使用亚硫酸钠-羧酸体系将芳香族硝基化合物轻松有效地还原酰化为相应的苯胺。硫化钠...
COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT
申请人:Lee Jung Joon
公开号:US20090306078A1
公开(公告)日:2009-12-10
Disclosed herein are an HIF-1 inhibitor, a method for the preparation thereof, and a pharmaceutical composition comprising the same as an active ingredient. The HIF-1 inhibitor shows anticancer activity thanks to the inhibition activity against HIF-1, a transcription factor which plays an important role in the growth and metastasis of cancer, but not to general cytotoxicity. Thus, the HIF-inhibitor and a pharmaceutically acceptable salt thereof can be used as a therapeutic for various cancers such as liver cancer; stomach cancer and breast cancer. Also, the compound having inhibition activity against HIF-1 is useful in the treatment of diabetic retinopathy and arthritis, which are aggravated by HIF-1-mediated VEGF expression.
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
申请人:Rodgers D. James
公开号:US20070135461A1
公开(公告)日:2007-06-14
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.